Effect of Recombinant Human Endostatin Injection Combined with Chemotherapy on Non-Small Cell Lung Cancer and Activated Circulating Endothelial Cells

Abstract

To explore the clinical efficacy of recombinant human endostatin injection combined with chemotherapy in the treatment of non-small cell lung cancer and the influence on activated circulating endothelial cells in peripheral blood. A total of 100 non-small cell lung cancer patients were selected and divided into combination and chemotherapy group. Another 30 healthy volunteers were selected as healthy control group. The shortterm treatment effects, drug side effects during treatment and long-term quality of life were compared. Enzyme-linked immunosorbent assay was used to detect the levels of vascular endothelial growth factor and basic fibroblast growth factor. Flow cytometry was used to detect the expression of CD105 and CD146. The total effective rate, leukopenia, thrombocytopenia, nausea/vomiting, peripheral neurotoxicity, cardiac injury and fever were significantly different between the two groups (p<0.05). The physical role, emotional, social and general health scores were significantly higher, and the fatigue, nausea and vomiting, pain, shortness of breath, loss of appetite, constipation, lung cancer specific modules and total symptom subscale score were significantly lower in combination group than those in chemotherapy group (p<0.05). The levels of vascular endothelial growth factor and basic fibroblast growth factor in combination group were decreased and activated circulating endothelial cells were increased after treatment, while in the chemotherapy group, activated circulating endothelial cells only increased in the 4th cycle (p<0.05). Endo combined with chemotherapy has a significant short-term effect in the treatment of non-small cell lung cancer, which can reduce side effects and improve the quality of life.